Evidence map›Paper›PMID 21049473›Full record

ArticleHepatology (Baltimore, Md.)2010

Type 2 diabetes in mice induces hepatic overexpression of sulfatase 2, a novel factor that suppresses uptake of remnant lipoproteins.

Keyang Chen, Ming-Lin Liu, Lana Schaffer, Mingzhen Li, Guenther Boden, Xiangdong Wu, Kevin Jon Williams

Open access · greenAbstract read
In one paragraph

Article in Hepatology (Baltimore, Md.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 55 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. The association between a genetic variant in theCardiovascular endocrinology & metabolism · 2023
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. The heparan sulfate proteoglycan grip on hyperlipidemia and atherosclerosis.Matrix biology : journal of the International Society for Matrix Biology · 2018
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Hyperlipoproteinemia type 3: the forgotten phenotype.Current atherosclerosis reports · 2014
    Review
  17. Article
  18. The regulation of ApoB metabolism by insulin.Trends in endocrinology and metabolism: TEM · 2013
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Keyang ChenSection of Endocrinology, Diabetes and Metabolism, Temple University School of Medicine, Philadelphia, PA 19140, USA.
Ming-Lin Liu
Lana Schaffer
Mingzhen Li
Guenther Boden
Xiangdong Wu
Kevin Jon Williams
Temple University · USScripps Research Institute · US

Funding

Structural Basis of Immune Recognition of Glycosylated AntigensU54GM062116 · NIGMS · SCRIPPS RESEARCH INSTITUTE, THE · PI PAULSON, JAMES C · 2001 to 2010
$80.3M
PROTEIN TYROSINE PHOSPHATASES IN INSULIN ACTIONR01DK043396 · NIDDK · THOMAS JEFFERSON UNIVERSITY · PI WILLIAMS, KEVIN JON · 1991 to 2009
$3.2M
HSPGs as remnant receptors: critical role in diabetic postprandial dyslipidemiaR01HL094277 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI WILLIAMS, KEVIN JON · 2009 to 2012
$1.5M
Endocytic Trafficking Motifs in Syndecan &LDL receptorR01HL073898 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI WILLIAMS, KEVIN JON · 2005 to 2008
$1.2M
Screens for novel compounds to correct diabetic postprandial dyslipidemiaR01HL093321 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI WILLIAMS, KEVIN JON · 2009 to 2011
$1.1M
NHLBI NIH HHS HL73898NHLBI NIH HHS HL93321NHLBI NIH HHS HL94277NHLBI NIH HHS R01 HL073898NHLBI NIH HHS R01 HL093321NHLBI NIH HHS R01 HL094277NIDDK NIH HHS DK43396NIDDK NIH HHS R01 DK043396NIGMS NIH HHS GM62116NIGMS NIH HHS U54 GM062116
6 · The paper itself

Abstract

unlabelledType 2 diabetes mellitus (T2DM) impairs hepatic clearance of atherogenic postprandial remnant lipoproteins. Our work and that of others have identified syndecan-1 heparan sulfate proteoglycans (HSPGs) as remnant lipoprotein receptors. Nevertheless, defects in the T2DM liver have not been molecularly characterized, and neither has the correction that occurs upon caloric restriction. We used microarrays to compare expression of proteoglycan-related genes in livers from control db/m mice; obese, T2DM db/db littermates fed ad libitum (AL); and db/db mice pair-fed to match the intake of db/m mice. Surprisingly, the arrays identified only one gene whose dysregulation by T2DM would disrupt HSPG structure: the heparan sulfate glucosamine-6-O-endosulfatase-2 (Sulf2). SULF2 degrades HSPGs by removing 6-O sulfate groups, but had no previously known role in diabetes or lipoprotein biology. Follow-up quantitative polymerase chain reaction assays revealed a striking 11-fold induction of Sulf2 messenger RNA in the livers of AL T2DM mice compared with controls. Immunoblots demonstrated induction of SULF2 in AL livers, with restoration toward normal in livers from pair-fed db/db mice. Knockdown of SULF2 in cultured hepatocytes doubled HSPG-mediated catabolism of model remnant lipoproteins. Notably, co-immunoprecipitations revealed a persistent physical association of SULF2 with syndecan-1. To identify mechanisms of SULF2 dysregulation in T2DM, we found that advanced glycosylation end products provoked a 10-fold induction in SULF2 expression by cultured hepatocytes and an approximately 50% impairment in their catabolism of remnants and very low-density lipoprotein, an effect that was entirely reversed by SULF2 knockdown. Adiponectin and insulin each suppressed SULF2 protein in cultured liver cells and in murine livers in vivo, consistent with a role in energy flux. Likewise, both hormones enhanced remnant lipoprotein catabolism in vitro.

conclusionSULF2 is an unexpected suppressor of atherogenic lipoprotein clearance by hepatocytes and an attractive target for inhibition.

Indexed as

AnimalsCaloric RestrictionDiabetes Mellitus, Type 2Glycation End Products, AdvancedHeparan Sulfate ProteoglycansHepatocytesLipoproteinsLiverMaleMiceRatsSulfatasesUp-RegulationGlycation End Products, AdvancedHeparan Sulfate ProteoglycansLipoproteinsSulf2 protein, mouseSulfatases

Identifiers

PMID21049473
PMCPMC2991429
OpenAlexW1978370459

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.